Clinical Trials Logo

Filter by:
NCT ID: NCT05557058 Recruiting - Clinical trials for Primary Open-angle Glaucoma

GORE Glaucoma Drainage Implant Clinical Study

Start date: September 14, 2022
Phase: N/A
Study type: Interventional

The objective of this early feasibility clinical study is to evaluate the safety and effectiveness of the GORE Glaucoma Drainage Implant (2 configurations) in subjects with primary open-angle glaucoma that is uncontrolled by hypotensive medications or for which conventional incisional glaucoma surgery would be more likely to fail due to scarring.

NCT ID: NCT05556772 Recruiting - Clinical trials for Malignant Female Reproductive System Neoplasm

Optimizing Screening for Cervical Cancer Among Women Living With HIV in the Dominican Republic

Start date: November 14, 2022
Phase: N/A
Study type: Interventional

This study compares different screening approaches to detect abnormal cell growth on the cervix that could be an early sign of cervical cancer. The lesions are caused by an infection of human papillomavirus, also called HPV. Using new methods to detect HPV may help doctors find ways to improve cervical cancer screening for women living with human immunodeficiency virus (HIV) in the Dominican Republic and in other countries.

NCT ID: NCT05520944 Active, not recruiting - COVID-19 Clinical Trials

Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis

Start date: August 26, 2021
Study type: Observational

The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care). The hypothesis to be tested is that patients treated with CPM nasal spray showed more rapid clinical improvement than those treated with standard of care alone. Clinical improvement will be evaluated by the total number of days with the manifestation of COVID-19 symptoms, including cough, nasal congestion, ageusia, and anosmia, among others. The rate of hospitalization between the cohorts will also be evaluated.

NCT ID: NCT05502341 Recruiting - HIV-1-infection Clinical Trials

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

Start date: August 16, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the efficacy of switching to a bictegravir (BIC) plus lenacapavir (LEN) regimen versus continuing on stable baseline regimen (SBR) in virologically suppressed people with human immunodeficiency virus (PWH) (Phase 2) and to evaluate the efficacy of switching to BIC/LEN fixed-dose combination (FDC) tablet regimen versus continuing on a SBR in virologically suppressed PWH (Phase 3).

NCT ID: NCT05468736 Recruiting - COVID-19 Clinical Trials

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Start date: July 22, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary doses and a booster dose of NVX CoV2373 given 21 days apart in pediatric participants (3 age cohorts; 6 to < 12 years, 2 to < 6 years, and 6 to < 24 months of age). Each age cohort will be conducted in 2 parts starting with the oldest age cohort (6 to < 12 years of age).

NCT ID: NCT05398185 Not yet recruiting - HIV Infections Clinical Trials

WiseApp for Spanish Speakers Living With HIV

Start date: January 2023
Phase: N/A
Study type: Interventional

This study aims to conduct a 12-month randomized controlled trial to adapt the mobile app, WiseApp, and a smart pill dispenser for Spanish-speaking people living with HIV (PLWH) in the New York City (NYC) area and La Romana, Dominican Republic (DR). The study will assess the efficacy and sustainability of WiseApp as well as identify barriers with its widespread use among Spanish speakers. With disproportionately high rates of HIV in the New York City area and the Dominican Republic, this project seeks to identify distinct contextual factors related to Spanish speaking people living with HIV and increase the likelihood of engagement with technology and improvements in clinical outcomes.

NCT ID: NCT05317728 Not yet recruiting - Cataract Clinical Trials

Clinical Study of a Fluid Accommodating Intraocular Lens (IOL) Design

Start date: March 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to evaluate the surgical, refractive, and visual outcomes with implantation of an investigational intraocular lens (IOL).

NCT ID: NCT05298423 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

Start date: May 3, 2022
Phase: Phase 3
Study type: Interventional

This study is to evaluate the safety and efficacy of pembrolizumab/vibostolimab (MK-7684A) in combination with concurrent chemoradiotherapy (cCRT) followed by pembrolizumab/vibostolimab versus cCRT followed by durvalumab in participants with unresectable, locally advanced, stage III Non-small Cell Lung Cancer (NSCLC). The primary hypotheses are that pembrolizumab/vibostolimab with cCRT followed by pembrolizumab/vibostolimab is superior to cCRT followed by durvalumab with respect to the following: - progression free survival (PFS) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 by blinded independent central review (BICR) in participants with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥1% and PD-L1 all comer participants. - overall survival (OS) in participants with PD-L1 TPS ≥1% and PD-L1 all comer participants.

NCT ID: NCT05295641 Recruiting - Heart Failure Clinical Trials

American Registry of Ambulatory or Acute Decompensated Heart Failure

Start date: April 1, 2022
Study type: Observational [Patient Registry]

The purpose of this study is to better characterize and understand the population of patients with ambulatory or acutely decompensated heart failure in the American continent, getting to know their sociodemographic, clinical and paraclinical characteristics

NCT ID: NCT05281094 Recruiting - Gastroenteritis Clinical Trials

Efficacy and Safety of Two Doses of HIL-214 in Children

Start date: March 16, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, placebo-controlled study that is being done to evaluate the safety and effectiveness of two doses of the HIL-214 vaccine compared to a placebo. The study will enroll 3000 children who will be 5 months of age at the time of the first dose study vaccine. The second dose of study vaccine will be given 28 days after the first dose.